Combined cord blood and bone marrow transplantation from the same human leucocyte antigen-identical sibling donor for children with malignant and non-malignant diseases by Tucunduva, Luciana et al.
Combined cord blood and bone marrow transplantation from
the same human leucocyte antigen-identical sibling donor for
children with malignant and non-malignant diseases
Luciana Tucunduva,1,2 Fernanda Volt,1
Renato Cunha,1 Franco Locatelli,3
Marco Zecca,4 Akif Yesilipek,5 Maurizio
Caniglia,6 Tayfun G€ung€or,7 Serap
Aksoylar,8 Franca Fagioli,9 Yves
Bertrand,10 Maria Carmen Addari,11
Josu de la Fuente,12 Jacek Winiarski,13
Andrea Biondi,14 Henrik Sengeloev,15
Isabel Badell,16 Karin Mellgren,17
Cristina Dı´az de Heredia,18 Petr
Sedlacek,19 Ajay Vora,20 Vanderson
Rocha,1,21 Annalisa Ruggeri1,22 and
Eliane Gluckman1,23 On behalf of
Eurocord and the EBMT Paediatric
working party
1Hospital Saint Louis, AP-HP, and IUH Univer-
sity Paris VII, Eurocord, Paris, France, 2Centro
de Oncologia, Hospital Sirio-Libanes, Sao Paulo,
Brazil, 3Dipartimento di Oncoematologia Pedia-
trica, Ospedale Bambino Gesu, IRCSS, Univer-
sita di Pavia, Rome, 4Fondazione IRCCS
Policlinico San Matteo, Pavia, Italy, 5Akdeniz
University Medical School, Antalya, Turkey,
6Dipartimento di Medicina Clinica e Sperimen-
tale, Universita di Perugia, Perugia, Italy, 7Stem
Cell Transplantation Department, University
Children’s Hospital, Z€urich, Switzerland, 8Ege
University, Izmir, Turkey, 9Ospedale Infantile
Regina Margherita Oncoematologia Pediatrica e
Centro Trapianti, Torino, Italy, 10Institut
d’Hematologie et d’Oncologie Pediatrique de
Lyon, Lyon, France, 11Centro Trapianti di Mid-
ollo Osseo Ospedale Microcitemico, Cagliari,
Italy, 12Division of Paediatrics, St. Mary’s Hospi-
tal, London, UK, 13Astrid Lindgren Children’s
Hospital, Huddinge, Karolinska Institutet,, Karo-
linska University Hospital, Stockholm, Sweden,
14Ospedale San Gerardo/Fondazione MBBM,
Clinica Pediatrica dell Universita` di Milano-Bic-
occa, Monza, Italy, 15Rigshospitalet, Copenhagen,
Denmark, 16Hospital Santa Creu i Sant Pau,
Barcelona, Spain, 17The Queen Silvia’s Hospital
for Children and Adolescents, Goeteborg, Sweden,
Summary
Umbilical cord blood (UCB) from an human leucocyte antigen (HLA)-
identical sibling can be used for transplantation of patients with malignant
and non-malignant diseases. However, the low cellular content of most
UCB units represents a limitation to this approach. An option to increase
cell dose is to harvest bone marrow (BM) cells from the same donor and
infuse them along with the UCB. We studied 156 children who received
such a combined graft between 1992 and 2011. Median age was 7 years
and 78% of patients (n = 122) were transplanted for non-malignant dis-
eases, mainly haemoglobinopathies. Acute leukaemia (n = 26) was the most
frequent malignant diagnosis. Most patients (91%) received myeloablative
conditioning. Median donor age was 17 years, median infused nucleated
cell dose was 244 9 107/kg and median follow-up was 41 months. Sixty-
days neutrophil recovery occurred in 96% of patients at a median of 17 d.
The probabilities of grade-II-IV acute and chronic graft-versus-host disease
(GVHD) were 19% and 10%, respectively. Four-year overall survival was
90% (68% malignant; 97% non-malignant diseases) with 3% probability of
death. In conclusion, combined UCB and BM transplantation from an
HLA-identical sibling donor is an effective treatment for children with
malignant and non-malignant disorders with high overall survival and low
incidence of GVHD.
Keywords: haematopoietic stem cell transplantation, cord blood, bone
marrow.
research paper
ª 2014 John Wiley & Sons Ltd
British Journal of Haematology, 2015, 169, 103–110
First published online 18 December 2014
doi: 10.1111/bjh.13267
18Hospital Vall d’Hebron, Barcelona, Spain,
19University Hospital Motol, Prague, Czech
Republic, 20Sheffield Children’s Hospital, Shef-
field, 21Department of Clinical Haematology,
Oxford University Hospitals NHS Trust, Oxford,
UK, 22Hospital Saint Antoine, Service d’He´ma-
tologie et The´rapie Cellulaire, AP-HP, Paris,
France, and 23Monacord, Centre Scientifique de
Monaco, Monaco, Monaco
Received 2 September 2014; accepted for
publication 17 November 2014
Correspondence: Eliane Gluckman, Ho^pital
Saint Louis, Eurocord, 1 av Claude Vellefaux,
Paris 75010, France.
E-mail: eliane.gluckman@sls.aphp.fr
Umbilical cord blood (UCB) was first used to treat a child
with Fanconi anaemia (Gluckman et al, 1989). Since then,
several studies have shown that umbilical cord blood trans-
plantation (UCBT) is as effective as other modalities of hae-
matopoietic stem cell transplantation (HSCT) to treat both
malignant and non-malignant haematological disorders
(Wagner et al, 1995; Kurtzberg et al, 1996; Gluckman et al,
1997, 2011a; Locatelli et al, 1999; Rocha et al, 2001, 2004;
Laughlin et al, 2004; Eapen et al, 2007; Ballen et al, 2013).
Since the institution of cord blood banks, the majority of
UCBT are performed using unrelated donor units (Wernet,
2004; Bart et al, 2013; Yoder, 2014). However, in selected
cases, a human leucocyte antigen (HLA) identical sibling
UCB can be used for the treatment of a patient in need of
transplantation (Gluckman et al, 2011b). One of the main
limitations of UCBT is the low cellular content of a single
UCB unit (Wagner et al, 2002; Warkentin, 2003; Gluckman
et al, 2004 Barker et al, 2010; Mazzocchetti et al, 2014), and
the association between cell dose and outcome after UCBT
has already been consistently demonstrated (Gluckman et al,
2004; Barker et al, 2010; Mazzocchetti et al, 2014). While
public unrelated cord blood banks have set stringent quality
criteria (Warkentin, 2003), UCB units available for related
use have often been stored in private facilities or local cell-
therapy units that do not always follow the same rules, espe-
cially those concerning the minimum number of total nucle-
ated cells (TNC) collected, as very often they are stored
regardless of the cellular content. The number of related cord
blood transplants is limited despite very good outcomes in
both malignant and non-malignant diseases, mostly because
of cost of UCBT and the lack of information from the fami-
lies and physicians (Gluckman et al, 1997, 2011a,b; Herr
et al, 2010; Sabloff et al, 2011; Locatelli et al, 2013). In the
related donor setting, an option to enhance the cellular con-
tent of a graft is to harvest bone marrow (BM) cells from
the same sibling donor and to infuse them in addition to the
UCB unit. To date, there are few published reports on this
approach (Dallorso et al, 1996; Goussetis et al, 2000).
This study aimed to describe transplantation outcomes in
children with either haematological malignant or non-malig-
nant diseases who received a combined graft of UCB and
BM from the same HLA identical sibling donor.
Methods
Data collection
Data on patients, UCB unit characteristics and outcomes
were collected from the Eurocord and the European Group
for Blood and Marrow Transplantation (EBMT) databases.
All patients or the responsible guardian gave informed con-
sent for data entry into the EBMT and Eurocord registries
databases and for its use for research in accordance with the
Declaration of Helsinki. The institutional review board of
Eurocord approved this study.
Selection criteria
The selection criteria for this study were: age less than 21 years;
transplantation performed between 1992 and 2011 in EBMT
centres; graft consisting of a combination of UCB and BM
from the same HLA identical sibling donor; and no history of
previous allogeneic transplantation. All consecutive transplants
meeting the study criteria (n = 156) were included. Transplan-
tations were performed in 57 centres. Median follow-up of sur-
vivors was 41 months (range 3–213).
Definitions and endpoints
Patients aged between 1 and ≤20 years were defined as chil-
dren, but only one patient in this study was older than
18 years of age.
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Human leucocyte antigen compatibility was determined by
serology for HLA-A and -B loci and by DNA typing for
HLA-DRB1 locus. Neutrophil engraftment was defined as
having an absolute neutrophil count ≥05 9 109/l for 3 con-
secutive days, excluding patients with evidence of autologous
reconstitution. Full donor chimerism was defined as ≥95%
leucocytes of donor origin in either peripheral blood or mar-
row samples, measured by different techniques according to
the transplantation centre. Autologous reconstitution was
defined as ≥95% leucocytes of recipient origin. Mixed chime-
rism was defined by the presence of >5% but <95% of leuco-
cytes of donor origin. Chimerism was analysed within 100 d
after transplantation. Primary graft failure was defined as the
absence of haematopoietic reconstitution of donor origin on
day +60 after transplantation. The diagnosis and grading of
acute and chronic graft-versus-host disease (GVHD) was per-
formed by the transplantation centre using standard criteria
(Przepiorka et al, 1995). Transplantation-related mortality
(TRM) was defined as death by any cause related to the
transplantation procedure. Overall survival (OS) was calcu-
lated from the date of UCBT until death or last observation
for surviving patients. The primary outcome of this analysis
was OS.
Statistical analysis
The probabilities of OS were calculated using the Kaplan–
Meier (Kaplan & Meier, 1958). Due to the small number of
competing events, the probabilities of neutrophil engraft-
ment, grade II–IV acute GVHD (aGVHD) and chronic
GVHD (cGVHD), graft failure, relapse and TRM were calcu-
lated using the Kaplan–Meier method. Univariate analyses
were performed using the log–rank test and included clini-
cally relevant variables related to the patient [gender, age at
transplantation and recipient cytomegalovirus (CMV) sero-
logical status], the disease (malignant versus non-malignant),
the procedure [year of transplantation, type of conditioning,
use of methotrexate (MTX) and anti-thymocyte globulin
(ATG) as GVHD prophylaxis] and the graft (number of
infused total nucleated cells and donor/recipient gender mis-
match). Multivariate analyses were performed using Cox pro-
portional hazards regression model (Cox, 1972). Variables
that reached a P-value of 015 in the univariate analysis were
included in the initial models and variables were eliminated
one at a time in a stepwise fashion in order to only keep
variables that reached a P-value of 005 in the final model.
P-values were two-sided. Statistical analyses were performed
with SPSS version 19 (SPSS Inc., Chicago, IL, USA).
Results
Patients
Patient (n = 156) and transplantation characteristics are
shown in Table I. Median age at HSCT was 7 years (range 1–
20). The vast majority of patients (n = 122, 78%) had non-
malignant diseases, the most common diagnosis being haemo-
globinopathy (n = 89, 57%), with 82 patients transplanted for
thalassaemia and seven for sickle cell disease. Other frequent
diagnoses were BM failure (BMF) (n = 24, 15%), with eight
cases of Fanconi anaemia, five of Blackfan–Diamond disease,
seven of other hereditary BMF and four of idiopathic aplastic
anaemia. Among the 34 patients transplanted for malignant
diseases, 26 had acute leukaemia and only two of them were
transplanted in first complete remission.
Transplantation
Conditioning was myeloablative in 142 (91%) patients and
busulfan- or treosulfan-based in 117 (82%) cases. A total
body irradiation (TBI)-based regimen was given to 19
patients. GVHD prophylaxis consisted of ciclosporin mono-
therapy in 71 patients (45%) and ciclosporin in combination
with MTX, with or without prednisone in 50 of them (32%).
ATG was used in 60 patients (38%), all of whom had non-
malignant disease.
Graft composition
Information was available regarding the reason for using a
combined graft for 126 of the 156 transplantations. In more
than 80% of cases (n = 104), centres reported that they esti-
mated that the number of TNC available in the UCB was
not sufficient for transplantation. For the remaining 22
patients, other reasons were reported, as follows: other rea-
son not specified, n = 16; patient had aplastic anaemia
refractory to immune suppression and a long history of
transfusion, n = 1; centre preference to use BM (instead of
UCB only) when an identical sibling is available and patient
can wait for transplant, n = 3; patient had minimal residual
disease at the time of transplant, therefore BM cells were
added to speed engraftment and boost graft-versus-leukaemia
effect, n = 1; the initial plan was to give BM only, but as
donor was only 4 months old, UCB was added to decrease
the amount of BM collected, n = 1.
Complete information on BM grafts was available for 114
cases. Median collected BM volume was 198 ml (range 15–
580). Table II shows the number of infused UCB TNC dose
per quartiles, as well as BM TNC dose. Adding BM cells to
the UCB increased the cellularity of the graft, resulting in a
median TNC dose of 244 9 107/kg (range 42–455 9 107/
kg). Of the 119 patients for whom the UBC TNC dose was
available, 14 patients with malignant diseases had an UCB
unit with a TNC content ≥25 9 107/kg and 37 patients with
non-malignant diseases had a UCB unit with a TNC dose
>35 9 107/kg, which is the recommended cell dose for
malignant and non-malignant diseases, respectively (Gluck-
man et al, 2011a; Scaradavou et al, 2013). The remaining 68
patients did not have a UCB unit with an adequate TNC
dose prior to the addition of the BM cells.
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Donors
Complete information regarding donors was available in 104
cases. There were no serious adverse effects reported after
BM harvest. Blood transfusion was required for 38 donors
(36%) – 31 received one unit, six received two or more units
of packed red blood cells. Median donor age at the time of
BM harvest was 17 years (range 03–143).
Engraftment and graft failure
Overall, the 60-d probability of neutrophil engraftment was
96  2%, and neutrophil recovery occurred at a median
time of 17 d (range 11–105) after transplantation. In univari-
ate analysis, the only risk factor associated with decreased
neutrophil engraftment was diagnosis of non-malignant dis-
ease (94% vs. 100% for non-malignant and malignant dis-
eases, respectively, P = 0007). Multivariate analysis was not
performed because the number of events was too small.
Six patients failed to achieve neutrophil engraftment. All
of them had non-malignant diseases (five thalassaemia and
one immunodeficiency). Chimerism information was avail-
able for five out of these six patients with primary graft fail-
ure; three had autologous recovery and two had mixed
chimerism within 100 d after transplantation. Five patients
are alive; two of them received a subsequent allograft.
Acute and chronic GVHD
Overall, 30 patients had aGVHD (15/122 with non-malignant
disease and 15/32 with malignant disease and two had miss-
ing information). Probability of grade II–IV aGVHD at day
100 was 19  3% (Fig 1) and the median time of onset was
24 d. On univariate analysis, diagnosis of malignant disease
(47  9% vs. 12  3%, P < 0001) and patient-negative
CMV serology (29  6% vs. 13  4%, P = 0013) were asso-
ciated with increased risk of aGVHD, but only the type of
disease was confirmed as an independent factor in multivari-
ate analysis (Hazard ratio 46 95% confidence interval 18–
114; P = 0001 for malignant diseases). Twelve patients pre-
sented grade III–IV aGVHD; six of them had non-malignant
and six malignant diseases.
A total of 15 patients presented cGVHD; 8/109 with non-
malignant and 7/32 with malignant diseases (12 and two
patients had missing information in each group of patients,
respectively). Probability of cGVHD at 4 years was 10  3%
(Fig 2) and the median time of onset was 110 d after HSCT.
Three of 15 patients who presented cGVHD had extensive
disease. The only risk factor associated with increased risk of
cGVHD was a diagnosis of malignant disease (18  7% vs.
6  2%, P = 0012).
Transplantation-related mortality and causes of death
The 4-year TRM was 3  2%. Overall, 16 patients died at a
median time of 16 months after HSCT (range 1–132).
Among them, 11 had malignant diseases (eight acute leukae-
mia and three solid tumour); nine patients died from disease
progression and two from cGVHD. Of the five patients with
non-malignant diseases who died, two had thalassaemia, two
immunodeficiency and one had BMF. Two of these patients
Table I. Patient and transplant characteristics.
Median follow-up (range) 41 (3–213) months
Median age (range) 7 (1–20) years
Median year of transplant (range) 2007 (1992–2012)
Previous ASCT 4
Diagnosis, n (%)
Malignant 34 (22)
ALL 22 (65)
AML 4 (12)
MDS/MPD 3 (9)
Non-Hodgkin lymphoma 2 (5)
Solid tumour 3 (9)
Non-malignant 122 (78)
Bone marrow failure syndrome 24 (20)
Haemoglobinopathy 89 (73)
Immune deficiency 7 (6)
Other 1 (1)
Disease status-malignant disease
only
32 (94) ≥CR2
Type of conditioning, n (%)
RIC 10 (7)
CY  FLU 8 (80)
Other 2 (20)
MAC 142 (93)
BU + CY 65 (46)
Treo + Other 22 (15)
BU + FLU + Thio 16 (11)
BU  Other 14 (10)
Other 25 (18)
TBI, n (%)
No 135 (88)
Yes 19 (12)
GVHD prophylaxis, n (%)
CsA 71 (49)
CsA + MTX  Other 52 (36)
CsA  Other 16 (11)
Other 5 (4)
Serotherapy (ATG or MoAb), n (%)
No 80 (57)
Yes 60* (43)
ASCT, autologous transplant; ALL, acute lymphoblastic leukaemia;
AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome;
MPD, myeloproliferative disease; RIC, reduced intensity condition-
ing; CY, cyclophosphamide; FLU, fludarabine; MAC, myeloablative
conditioning; BU, busulfan; Treo, treosulfan; Thio, thiothepa; TBI,
total body irradiation; CsA, ciclosporin; MTX, methotrexate; ATG,
anti-thymocyte globulin; MoAb, monoclonal antibody; CR2, second
complete remission.
Missing data: type of conditioning (RIC vs. MAC), n = 4; TBI,
n = 2; GVHD Prophylaxis n = 12; ATG, n = 16.
*All 60 patients who received ATG had non-malignant diseases.
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died of rejection (one after primary and other of secondary
graft failure) and the remaining three of infections.
Survival
Overall survival at 4 years was 90  3%; it was 97  2% for
non-malignant and 68  9% for malignant diseases
(P < 0001; Fig 3). Out of 34 patients with malignant dis-
eases, 12 relapsed at a median time of 11 months after HSCT
(range 3–32). There were no other risk factors, besides diag-
nosis, associated with survival, even when analysing patients
with malignant and non-malignant diseases separately.
Discussion
The use of related UCBT has been limited by the availability
and cost of a good quality product. In the Eurocord data-
base, 782 related UCBT have been reported since 1988, with
an even distribution across the years, except for the first few
years. The main indication for related UCBT is haemoglobin-
opathy (Locatelli et al, 2013). The advantage of using related
UCB instead of BM from the same HLA-identical sibling is
the absence of risk to the donor and the decreased rate of
GVHD (Rocha et al, 2000).
One of the main concerns is the cellular content of the
stored unit because, in directed donations, UCB may be
stored even when the requirement for minimum cellular con-
tent is not met. In related UCBT, the use of BM from the
same HLA-identical donor has been proposed as a way to
increase the number of cells infused. Alternatively, in order
to facilitate engraftment, several authors have reported the
addition of third party stem cells with some success (Barker
et al, 2005; Bautista et al, 2009). Our study shows that com-
bined UCB and BM transplantation is associated with high
probability of neutrophil engraftment and very low mortality,
translating into excellent survival both for non-malignant
and malignant haematological diseases.
Most centres reported that the main reason for using
combined UCB and BM cells was to improve the cellular
content of the graft. Indeed, as presented in Table II, one
can see that, even in the fourth quartile, the UCB cell dose
was insufficient to transplant patients with non-malignant
diseases, according to established cord blood units choice cri-
teria, in which the recommended TNC threshold is
35 9 107/kg of recipient weight (Gluckman et al, 2011a). In
our study, we found a neutrophil engraftment rate of 96% in
a median time of 17 d, which is comparable with those
observed using BM grafts in previous studies using HLA-
identical sibling donors. Rocha et al (2000) reported an
engraftment rate of 98% after BM transplantation and 89%
after UCBT, with median time to engraftment of 18 and
Table II. Donor and graft characteristics.
Donor and graft
characteristics Median Range Quartile
Age, years 165 03–143
BM volume collected, ml 198 15–580
BM TNC infused, 9
107/kg
2190 25–451
UCB TNC infused, 9
107/kg
21 01–175 1st: 136
2nd: 210
3rd: 350
Combined (UCB + BM)
TNC infused, 9 107/kg
244 420–4551
BM, bone marrow; TNC, total nucleated cells; UCB, umbilical cord
blood.
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Fig 1. 100-days incidence of acute graft-versus-host disease (aGVHD).
Data missing for two patients; n = 154.
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Fig 2. Four-year incidence of chronic graft-versus-host disease
(cGVHD). Evaluable patients, n = 151).
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26 d, respectively. Of note, we observed a low overall proba-
bility of both acute and cGVHD, reflecting the GVHD rate
observed in the non-malignant population, which represents
the majority of patients in the study.
The benefit of a combined graft is rather evident, given
the improved outcome associated with the increased cellu-
larity brought by the addition of BM to the UCB graft,
but our results shine light on another important issue,
namely, that the possibility of combining UCB and BM in
the same graft may have an impact in the incidence of
GVHD. Rocha et al (2000) previously reported that, in the
related donor setting, UCBT is associated with a decreased
risk of both acute and chronic GVHD, compared to BM
transplantation. Also, a recent publication showing compa-
rable outcomes of children with haemoglobinopathies given
either an UCB (n = 96) or BM (n = 389) HLA-identical
sibling graft confirms a decreased risk of GVHD associated
with UCBT (21% vs. 11% for aGVHD and 12% vs. 5% for
cGVHD in BM and UCB recipients, respectively; Locatelli
et al, 2013). In a recent study on 149 thalassaemia patients
transplanted with HLA-identical sibling BM grafts, the inci-
dence of aGVHD was reported to be 38% and the 5-year
incidence of cGVHD was 13% (Sabloff et al, 2011); both
these values are higher than those found in our study
(12% and 6% for cGVHD and aGVHD, respectively) for
patients with non-malignant diseases. Another recent publi-
cation comparing outcomes of transplantations of com-
bined UCB and BM cells (n = 13) with those of CBT
(n = 25) and BMT (n = 21) alone also observed a trend
towards a higher incidence of acute and chronic GVHD in
patients receiving BMT compared to combined or UCB
grafts (Soni et al, 2014). Considering our results, it seems
that the addition of UCB cells to an HLA-identical sibling
BM graft might have an immunomodulatory effect, leading
to decreased GVHD risk. Nevertheless, it is important to
note that the present study is not a comparative study;
therefore we can only speculate that the addition of UCB
may play a role in the lower incidence of GVHD seen with
the non-malignant disorders.
Another relevant issue regards donor safety. Although har-
vesting BM from young children seems to be safe, with no
serious adverse effects reported in this study, we observed
that a high proportion of donors received red blood cell
transfusions (36%). In fact we were surprised by the high
number of transfusions; we were able to contact some centres
and ask for further information regarding the transfusions,
but most of them could not answer precisely because the
physicians taking care of the patients were no longer in
charge; others replied that it was standard institution practice
at the time of the transplantation. The risk associated with
these transfusions and general anaesthesia needs to be con-
sidered (Styczynski et al, 2012; Shah et al, 2014).
One may wonder why give UCB in combination with BM
instead of BM alone? Besides the possible immunomodula-
tory characteristics of UCB discussed previously, having the
UCB cells available may allow for a smaller BM harvest in a
rather young donor.
In conclusion, combined UCB and BM transplantation is
associated with excellent outcomes, both for malignant and
non-malignant diseases. The possibility of decreasing acute
and chronic GVHD by combining UCB with BM cells
deserves further biological and clinical investigations. Fur-
thermore, when the related UCB has a low pre-freezing TNC
dose, harvesting BM from the same donor to use in combi-
nation with UCB in the same transplantation procedure is a
suitable option.
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